Poolbeg Pharma (POLB) Competitors

GBX 11.40

+0.25 (+2.24%)

(As of 09/6/2024 11:10 AM ET)

Stock Analysis Chart Competitors Headlines Insider Trades

POLB vs. VRP, BVXP, HVO, ARIX, 4BB, SCLP, CIR, TILS, FUM, and VSN

Should you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Verona Pharma plc (VRP.L) (VRP), Bioventix (BVXP), hVIVO (HVO), Arix Bioscience (ARIX), 4basebio (4BB), Scancell (SCLP), Circassia Group (CIR), Tiziana Life Sciences (TILS), Futura Medical (FUM), and Verseon (VSN). These companies are all part of the "biotechnology" industry.

Poolbeg Pharma vs.

Poolbeg Pharma (LON:POLB) and Verona Pharma plc (VRP.L) (LON:VRP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

: 1.1% of Poolbeg Pharma shares are held by institutional investors. 25.4% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Verona Pharma plc (VRP.L)'s return on equity of 0.00% beat Poolbeg Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Poolbeg Pharma N/A -24.00% -16.87%
Verona Pharma plc (VRP.L) N/A N/A N/A
: In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Verona Pharma plc (VRP.L)'saverage media sentiment score.
Company Overall Sentiment
Poolbeg Pharma Neutral
Verona Pharma plc (VRP.L) Neutral
: Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Poolbeg Pharma N/A N/A -£3.93M -£0.01 -1,140.00
Verona Pharma plc (VRP.L) N/A N/A N/A -£32.70 N/A
: Verona Pharma plc (VRP.L) received 227 more outperform votes than Poolbeg Pharma when rated by MarketBeat users.
Company Underperform Outperform
Poolbeg Pharma N/A N/A
Verona Pharma plc (VRP.L) Outperform Votes
227
64.67%
Underperform Votes
124
35.33%
: Given Verona Pharma plc (VRP.L)'s higher probable upside, analysts clearly believe Verona Pharma plc (VRP.L) is more favorable than Poolbeg Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Poolbeg Pharma
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Verona Pharma plc (VRP.L)
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-24.00%	-16.87%
Verona Pharma plc (VRP.L)	N/A	N/A	N/A

Company	Overall Sentiment
Poolbeg Pharma	Neutral
Verona Pharma plc (VRP.L)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£3.93M	-£0.01	-1,140.00
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A

Company	Underperform	Outperform
Poolbeg Pharma	N/A	N/A
Verona Pharma plc (VRP.L)	Outperform Votes 227 64.67%	Underperform Votes 124 35.33%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Poolbeg Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Verona Pharma plc (VRP.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Verona Pharma plc (VRP.L) beats Poolbeg Pharma on 5 of the 8 factors compared between the two stocks.

Ad Behind the Markets

NASDAQ to crash 50%?

During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...

Click here to learn more >>>

Get Poolbeg Pharma News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POLB vs. The Competition

Export to Excel

Metric	Poolbeg Pharma	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£57M	£150.36M	£5.67B	£1.52B
Dividend Yield	N/A	3.51%	2.73%	10.85%
P/E Ratio	-1,140.00	112.19	114.96	1,795.01
Price / Sales	N/A	15,064.51	1,747.67	380,086.50
Price / Cash	2.11	12.30	38.68	36.12
Price / Book	3.80	4.93	4.94	2.70
Net Income	-£3.93M	-£19.20M	£114.59M	£154.92M
7 Day Performance	-6.17%	-0.14%	-1.52%	-1.51%
1 Month Performance	-4.74%	3.11%	8.44%	0.24%
1 Year Performance	66.16%	12.41%	12.44%	94.45%

Poolbeg Pharma Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRP Verona Pharma plc (VRP.L)	0 of 5 stars 0.00 / 5 stars	GBX 55 +5.8%	N/A	N/A	£228M	N/A	-1.68	22	Gap Up
BVXP Bioventix	0 of 5 stars 0.00 / 5 stars	GBX 4,110 -3.3%	N/A	+4.4%	£214.54M	£13.60M	2,521.47	12	News Coverage Gap Down
HVO hVIVO	0 of 5 stars 0.00 / 5 stars	GBX 28.75 -1.7%	N/A	+62.4%	£195.61M	£58.67M	1,437.50	N/A
ARIX Arix Bioscience	0 of 5 stars 0.00 / 5 stars	GBX 142 flat	N/A	+25.1%	£183.73M	£14.16M	1,290.91	9
4BB 4basebio	0 of 5 stars 0.00 / 5 stars	GBX 1,406 -6.3%	N/A	+139.0%	£180.11M	£311,000.00	-2,267.74	78	Gap Up
SCLP Scancell	0 of 5 stars 0.00 / 5 stars	GBX 16.86 +0.7%	N/A	+83.8%	£156.74M	£5.27M	-1,686.10	51
CIR Circassia Group	0 of 5 stars 0.00 / 5 stars	GBX 34 -6.8%	N/A	+0.0%	£142.66M	£27.90M	3,400.00	111	News Coverage Gap Down
TILS Tiziana Life Sciences	0 of 5 stars 0.00 / 5 stars	GBX 58.50 +8.3%	N/A	+0.0%	£113.85M	£-3,595,000.00	-3.59	11
FUM Futura Medical	0 of 5 stars 0.00 / 5 stars	GBX 37.30 -1.6%	N/A	-23.7%	£112.59M	£3.10M	-1,865.00	12
VSN Verseon	0 of 5 stars 0.00 / 5 stars	GBX 74 +2.1%	N/A	+0.0%	£112.24M	N/A	-5.17	N/A	Gap Up